# 10x Genomics, Inc.  Share Price Target ‘$57.79’, now 22.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/10x-genomics-inc.share-price-target-57.79-now-22.5-upside-potential/4121145262
- Published: 2024-02-29T14:18:28+00:00
- Author: Charlotte Edwards

**10x Genomics, Inc.** with ticker code (TXG) have now 14 analysts in total covering
the stock. The consensus rating is pointing to ‘buy’. The range between the high
target price and low target price is between $70.00 and $30.00 calculating the mean
target share price we have $57.79. (at the time of writing). Now with the previous
closing price of $47.16 this indicates there is a potential upside of 22.5%. It’s
also worth noting that there is a 50 day moving average of $48.25 and the 200 moving
average now moves to $48.69. The market capitalization for the company is 5.56B.
The stock price for the company is currently $46.69 USD

 The potential market cap would be $6,818,027,771 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $5.28 and
a -12.22% return on assets.

10x Genomics, Inc. is a life science technology company. The Company’s integrated
platform solutions include instruments, consumables and software for analyzing biological
systems. Its Chromium platform includes its Chromium X Series, Chromium Connect 
and legacy Chromium Controller instruments, microfluidic chips and related consumables,
enables throughput analysis of individual biological components. Its Visium platform
enables researchers to understand the spatial positions of biological analytes within
tissues at high resolution. Its products include Chromium Single Cell Gene Expression,
Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling,
Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium
Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, Visium
Spatial Proteogenomics and Xenium In Situ Gene Expression. Its patent portfolio 
comprises over 1,750 issued patents and patent applications.

Share on:
